Literature DB >> 20063038

Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents.

Jose Córdoba-Chacón1, Manuel D Gahete, Mario Duran-Prado, Ana I Pozo-Salas, María M Malagón, F Gracia-Navarro, Rhonda D Kineman, Raul M Luque, Justo P Castaño.   

Abstract

Somatostatin and cortistatin exert multiple biological actions through five receptors (sst1-5); however, not all their effects can be explained by activation of sst1-5. Indeed, we recently identified novel truncated but functional human sst5-variants, present in normal and tumoral tissues. In this study, we identified and characterized three novel truncated sst5 variants in mice and one in rats displaying different numbers of transmembrane-domains [TMD; sst5TMD4, sst5TMD2, sst5TMD1 (mouse-variants) and sst5TMD1 (rat-variant)]. These sst5 variants: (1) are functional to mediate ligand-selective-induced variations in [Ca(2+)]i and cAMP despite being truncated; (2) display preferential intracellular distribution; (3) mostly share full-length sst5 tissue distribution, but exhibit unique differences; (4) are differentially regulated by changes in hormonal/metabolic environment in a tissue- (e.g., central vs. systemic) and ligand-dependent manner. Altogether, our results demonstrate the existence of new truncated sst5-variants with unique ligand-selective signaling properties, which could contribute to further understanding the complex, distinct pathophysiological roles of somatostatin and cortistatin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063038     DOI: 10.1007/s00018-009-0240-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  77 in total

1.  The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

Authors:  Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-18       Impact factor: 11.205

Review 2.  Somatostatin and somatostatin receptors in Cushing's disease.

Authors:  Leo J Hofland
Journal:  Mol Cell Endocrinol       Date:  2007-11-22       Impact factor: 4.102

3.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

Review 4.  Cell-based assays in GPCR drug discovery.

Authors:  Sandra Siehler
Journal:  Biotechnol J       Date:  2008-04       Impact factor: 4.677

5.  Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity.

Authors:  T Namba; Y Sugimoto; M Negishi; A Irie; F Ushikubi; A Kakizuka; S Ito; A Ichikawa; S Narumiya
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

6.  Severity of the catabolic condition differentially modulates hypothalamic expression of growth hormone-releasing hormone in the fasted mouse: potential role of neuropeptide Y and corticotropin-releasing hormone.

Authors:  Raul M Luque; Seungjoon Park; Rhonda D Kineman
Journal:  Endocrinology       Date:  2006-10-12       Impact factor: 4.736

7.  Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists.

Authors:  D Cervia; P Zizzari; B Pavan; E Schuepbach; D Langenegger; D Hoyer; C Biondi; J Epelbaum; P Bagnoli
Journal:  Neuropharmacology       Date:  2003-04       Impact factor: 5.250

8.  Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery.

Authors:  D Fehlmann; D Langenegger; E Schuepbach; S Siehler; D Feuerbach; D Hoyer
Journal:  J Physiol Paris       Date:  2000 May-Aug

9.  Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice.

Authors:  Raul M Luque; Zhi H Huang; Bhumik Shah; Theodore Mazzone; Rhonda D Kineman
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-11-22       Impact factor: 4.310

10.  Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.

Authors:  Raul M Luque; Rhonda D Kineman
Journal:  Endocrinology       Date:  2006-03-02       Impact factor: 4.736

View more
  24 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.

Authors:  Raúl M Luque; Alejandro Ibáñez-Costa; Leonardo Vieira Neto; Giselle F Taboada; Daniel Hormaechea-Agulla; Leandro Kasuki; Eva Venegas-Moreno; Alberto Moreno-Carazo; María Ángeles Gálvez; Alfonso Soto-Moreno; Rhonda D Kineman; Michael D Culler; Manuel D Gahete; Mônica R Gadelha; Justo P Castaño
Journal:  Cancer Lett       Date:  2015-01-28       Impact factor: 8.679

3.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

4.  BNGR-A25L and -A27 are two functional G protein-coupled receptors for CAPA periviscerokinin neuropeptides in the silkworm Bombyx mori.

Authors:  Zhangfei Shen; Yu Chen; Lingjuan Hong; Zhenteng Cui; Huipeng Yang; Xiaobai He; Ying Shi; Liangen Shi; Feng Han; Naiming Zhou
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

5.  Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.

Authors:  Walaa Alshafie; Yingzhou Edward Pan; Hans-Jürgen Kreienkamp; Thomas Stroh
Journal:  Endocrine       Date:  2020-05-07       Impact factor: 3.633

Review 6.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin.

Authors:  José Córdoba-Chacón; Manuel D Gahete; Ana I Pozo-Salas; Antonio J Martínez-Fuentes; Luis de Lecea; Francisco Gracia-Navarro; Rhonda D Kineman; Justo P Castaño; Raul M Luque
Journal:  Endocrinology       Date:  2011-10-04       Impact factor: 4.736

Review 8.  Does the pituitary somatotrope play a primary role in regulating GH output in metabolic extremes?

Authors:  Raul M Luque; Manuel D Gahete; Jose Cordoba-Chacon; Gwen V Childs; Rhonda D Kineman
Journal:  Ann N Y Acad Sci       Date:  2011-03       Impact factor: 5.691

Review 9.  Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2012-12-31       Impact factor: 3.750

10.  Expression of ZNF804A in human brain and alterations in schizophrenia, bipolar disorder, and major depressive disorder: a novel transcript fetally regulated by the psychosis risk variant rs1344706.

Authors:  Ran Tao; Helena Cousijn; Andrew E Jaffe; Philip W J Burnet; Freya Edwards; Sharon L Eastwood; Joo Heon Shin; Tracy A Lane; Mary A Walker; Brady J Maher; Daniel R Weinberger; Paul J Harrison; Thomas M Hyde; Joel E Kleinman
Journal:  JAMA Psychiatry       Date:  2014-10       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.